The Relationship of single nucleotide polymorphisms in the Interleukin-7 receptor-gene to CD4+ immune recovery in HIV infected patients who begin antiretroviral treatment with HAART

HMRC0 sites110 target enrollmentSeptember 23, 2005

Overview

Phase: 未知
Intervention: Not specified
Conditions: The determinants of immune recovery following institution of Highly Active Antiretroviral Treatment in HIV infected patients
Sponsor: HMRC
Enrollment: 110
Status: Completed
Last Updated: 6 years ago

No summary available.

Registry

who.int

Start Date

September 23, 2005

End Date

TBD

Last Updated

6 years ago

Study Type

Observational

Sex

All

Sponsor

HMRC

•First antiretroviral regimen composed of HAART as defined by at least three antiretrovirals. Controlled viremia for a period of at least 12 months following commencement of HAART. Controlled viremia is defined as HIV viral load of 500 copies/mL on bDNA testing (versions 2 and 3\) and \<400 copies/ml measured by RT\-PCR assay by 6 months treatment. CD4 cell count \<500 at commencement of HAART. Measurement of CD4\+ cell count on at least 3 time points, in the 12 months post commencement of HAART.

•Exclude patients treated for HIV seroconversion illness. Exclude patients on immunomodulatory therapy such as IL\-2, hydroxyurea or prednisolone or who have received an HIV therapeutic vaccine.